Search Results
Showing Results for transcatheter aortic valve replacement (TAVR)
May 2025 saw several significant developments in the field of cardiology, including new regulatory approvals, long-term clinical trial data and important findings from late-breaking studies. This roundup highlights the latest updates across structural, interventional and heart failure therapies, with implications for ...
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment ...
Over the past two decades, the field of transcatheter aortic valve replacement (TAVR) has experienced remarkable advancement. Initially approved for patients with high and prohibitive surgical risk, TAVR has progressively extended its indications to all patients, regardless of surgical risk. ...
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New ...
The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common ...
In recent years, patients undergoing non-emergent percutaneous coronary intervention (PCI) procedures have become increasingly older, with a more significant comorbidity burden and complex coronary disease.1 Many of the patients who undergo elective or urgent PCI are surgical turndown patients, for ...
The PROTECTED-TAVR trial studied the efficacy of using an embolic protection device (Sentinel® cerebral protection system) during transcatheter aortic valve replacement in reducing the incidence of stroke/disabling stroke. In this touchCARDIO interview, we speak with Dr Steven Messe (University ...
Both the CoreValve US pivotal and SURTAVI trials investigated the five-year incidence, timing and predictors of haemodynamic valve deterioration of transcatheter aortic valve replacement (TAVR) surgery and surgical aortic bioprostheses in the treatment of severe, symptomatic aortic stenosis. Prof. Michael ...
touchCARDIO spoke to Dr Duk-Woo Park (Asan Medical Center, Seoul, South Korea) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the ADAPT-TAVR trial of edoxaban versus dual antiplatelet therapy for valve thrombosis ...
Transcatheter-based therapies have become central to the treatment of valvular heart disease, particularly aortic stenosis.1–5 The first transcatheter aortic valve replacement (TAVR) was performed in 2002 and, in two short decades, TAVR has become a mainstay for the treatment of aortic ...
Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk ...
Aortic stenosis is a common degenerative valve disease and its prevalence increases with age.1 If untreated, severe symptomatic aortic stenosis leads to significant morbidity and mortality.2 Although surgical aortic valve replacement (SAVR) is a well-established treatment option for this condition, ...
Individuals with aortic stenosis frequently have coronary artery disease (CAD).1 Both conditions share a common pathophysiology involving low‐density lipoprotein-mediated inflammatory response, resulting in an accelerated atherosclerotic process.2 They also share similar risk factors, such as age, smoking, hypertension, diabetes ...
Background: Permanent pacemaker implant (PPI) is a frequent complication of transcatheter aortic valve replacement (TAVR), with potential long-term implications for patient morbidity and mortality. TAVR is expected to expand towards the treatment of lower-risk patients and other aortic valve pathologies; ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
